ライフサイエンスコーパス: SAPS

1 SAPS 3, CURB-65, CRB-65,and qSOFA all exhibited poor per

2 SAPS ensures that a significant gene set is not only abl

3 SAPS II (P < .001), hematoma volume (P = .01), and retro

4 SAPS II, APACHE II, and APACHE IV discriminated best; ov

5 SAPS is a powerful new method for deriving robust progno

6 SAPS-II score was the sole predictor of failure.

7 scores (Simplified Acute Physiology Score 3 [SAPS 3] and Sepsis-Related Organ Failure Assessment [qSO

8 We report here finding a SAPS sequence domain encoded in only a single gene each

9 ed at least one dose of study drug and had a SAPS assessment at baseline and at least one follow-up.

10 osed of the PP6 catalytic subunit bound to a SAPS domain scaffold subunit that associates with Ankrd2

11 atio, 1.93; 95% CI, 1.26-2.94; P = .002) and SAPS II, whereas immunosuppression and myocarditis as th

12 hreshold probability range for APACHE IV and SAPS-R.

13 inative ability of APACHE II, APACHE IV, and SAPS II was acceptable to excellent, whereas calibration

14 ng standard measures achieve significance by SAPS.

15 An easy-to-calculate score combining SAPS II and serum albumin level is a good prediction of

16 itive Symptoms-Hallucinations and Delusions (SAPS-H+D, with higher scores indicating greater psychosi

17 Tagged PP6 coprecipitated endogenous SAPS domain subunits and Ankrd28.

18 3 ( >.14) for MPM II0, and 8.17 (p >.42) for SAPS II, after customization.

19 tic curve was 0.83 for MPM II0 and 0.872 for SAPS II following model customization.

20 nd ICU discharge within 30 days adjusted for SAPS 3 score.

21 value for SOFA was 0.12 (0.05-0.15) and for SAPS-II 0.30 (0.08-0.48).

22 r operating characteristic curve (AUROC) for SAPS-II was 0.78 (95% CI 0.77-0.78) and 0.71 (0.70-0.72)

23 ted probability of in-hospital mortality for SAPS II was 0.72 (95% confidence interval, 0.57-0.87), f

24 ta support the notion that FyPP1/3, SAL (for SAPS DOMAIN-LIKE), and PP2AA proteins (RCN1 [for ROOTS C

25 This study used a human SAPS domain subunit FLAG-PP6R1 to identify endogenous in

26 howed differential distribution of the human SAPS-related mRNA in multiple human tissues, named as PP

27 Median simplified acute physiology score-II (SAPS-II) was 26.

28 ICU mortality calculators (e.g., APACHE II, SAPS II).

29 explanatory variables were categorised as in SAPS-II, and of 0.88 (0.87-0.89) when the same explanato

30 erin was associated with a -5.79 decrease in SAPS-PD scores compared with -2.73 for placebo (differen

31 For surviving patients, mean SAPS II was 19.6 +/- 7.1 (range, 13-31) and mean hematom

32 For deceased patients, mean SAPS II was 42 +/- 13.2 (range, 18-63) and mean hematoma

33 24,508 patients were included, with median SAPS-II of 38 (IQR 27-51) and median SOFA of 5 (IQR 2-8)

34 Customization of SAPS II and MPM II0 to the Project IMPACT database resul

35 Customized versions of SAPS II and MPM II0 were obtained by fitting new logisti

36 re (Pneumonia Shock score) that outperformed SAPS 3, CURB-65, and CRB-65.

37 ified Acute Physiology Score (SAPS)-Reduced (SAPS-R)' and Simplified Mortality Score for the ICU mode

38 nd functioning were measured using the SANS, SAPS, BPRS, and GSF/GRF.

39 ears old, simplified acute physiology score (SAPS) II 61 +/- 20) who underwent ECMO support for >48 h

40 ed on the Simplified Acute Physiology Score (SAPS) II and serum albumin level calculated before NPPV

41 The Simplified Acute Physiology Score (SAPS) II was higher during the first time period (38 [29

42 ACHE III, Simplified Acute Physiology Score (SAPS) II, and Mortality Probability Models (MPM) II were

43 success, simplified acute physiology score (SAPS) II, anticoagulation, embolic agent, hematoma volum

44 New Simplified Acute Physiology Score (SAPS) II, Morbidity Probability Model at admission (MPM0

45 PACHE IV, Simplified Acute Physiology Score (SAPS)-Reduced (SAPS-R)' and Simplified Mortality Score f

46 otic symptom severity (PANSS positive score, SAPS, AMDP ego-disorder) as well as response latencies d

47 BIAS is benchmarked against SEG, SAPS and CAST programs.

48 The results show SAPS domain subunits recruit substrates such as IkappaBe

49 nificance Analysis of Prognostic Signatures (SAPS) which integrates standard prognostic tests with a

50 call stochastically annealed product spaces (SAPS).

51 d scale for assessment of positive symptoms (SAPS-PD) in all patients who received at least one dose

52 The SAPS domain of PP6R1 alone was sufficient for associatio

53 The SAPS proteins are more divergent in sequence than PP6.

54 edicts that conserved sequence motifs in the SAPS domain accounts for the specificity.

55 ables were the same as those included in the SAPS II score.

56 ollowing: an increase of at least 30% in the SAPS-H+D score and a CGI-I score of 6 (much worse) or 7

57 ed on the 17 variables as they appear in the SAPS-II score (SL1), and the second, on the original, un

58 This role is mediated by a protein of the SAPS-domain family involved in S-phase entry.

59 We propose that the SAPS and ankyrin repeat regulatory subunits determine th

60 Cox regression analysis revealed that the SAPS II, medical cause of admission, mechanical ventilat

61 We use SAPS to perform a large meta-analysis (the largest compl

62 ive of mortality, outperforming models using SAPS II and OASIS scores, AUROC 0.72 and 0.76 at 24 h re

63 ted with PP6, not with PP2A or PP4, and with SAPS domain subunits PP6R1 and PP6R3.

64 PP6 called Sit4 depends on association with SAPS domain subunits.

65 rtality based on Super Learner compared with SAPS-II, APACHE-II, and SOFA.